Clinical Trial

Comparing Immune Response of 2 vs 3 HPV Doses (27-45 Years Old)

Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to compare a 2-dose and 3-dose series of 9vHPV vaccine among 27-45-year-old females to assess if 2 doses elicit a noninferior immune response. Participants will be randomized 1:1 to either the 2-dose group or the 3-dose group and asked to provide 4 blood samples over a period of 12 months. All 2-dose participants will be offered a 3rd dose after the final blood draw,12 months after their initial vaccination.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2022-12-21; most recent amendment 2025-10-02.
Status change: Not Yet Recruiting → Recruiting 2023-01-30
Trial Details
NCT Number NCT05672927
Lead Sponsor The University of Texas Medical Branch, Galveston
Collaborators: Cancer Prevention Research Institute of Texas
Conditions Immunization, HPV Infection, Human Papillomavirus
Enrollment 618 participants
Start Date 2023-01-18
Primary Completion 2026-08 (estimated)
Study Completion 2027-08 (estimated)
Updated on ClinicalTrials.gov 2025-10-06